Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
New research finds that MHC-II molecules have more influence on tumors than MHC-I

New research finds that MHC-II molecules have more influence on tumors than MHC-I

Cancer immunotherapy — efforts to boost a patient’s own immune system, allowing it to better fight cancer cells on its own — has shown great promise for some previously intractable cancers. Yet immunotherapy doesn’t work for everyone, for reasons that aren’t always clear. Most research and new therapies in this field have been focused on CD8+ T cells, a type of immune cell that recognizes and destroys other cells that display cancer antigens (mutated proteins that help give rise to tumors). Meanwhile, another type of immune cell, CD4+ T cells, and the molecular signals they recognize have received less attention.

Using a bioinformatics approach, University of California San Diego School of Medicine researchers found that CD4+ T cell’s binding partner, a molecule called MHC-II, may have even more influence on emerging tumors than MHC-I, the better known partner of CD8+ T cells.

The finding, published September 20 in Cell, may help researchers improve cancer immunotherapies and predict which patients will respond best.

“The more we know about the ability of a person’s immune system to clear cancer cells before they take hold, and the more we can combine that with other information about their inherited risk factors or environmental exposures, the better we may get at predicting a person’s cancer susceptibility,” said senior author Hannah Carter, PhD, assistant professor of medicine at UC San Diego School of Medicine. Carter led the study with first author Rachel Marty, a graduate student in her lab.

Know your MHCs

Carter and Marty’s study centers on the Major Histocompatibility Complex (MHC), a family of molecules displayed on the surface of most cells in the body. MHCs hold out antigens — bits of just about everything from inside the cells — and display them to T cells, immune system surveyors that are constantly checking for infected or damaged cells. If T cells spot MHC molecules with “self” antigens, they leave the cell alone. But if they spot foreign antigens, like those from bacteria or viruses, or mutated self-antigens, they kill the cell before the damage spreads.

In a previous Cell study, Carter, Marty and team found clear associations between a person’s MHC-I genetic makeup and the genes mutated in that person’s cancer. That makes sense, Carter said, since cancer antigens that are presented by MHC-I would lead to early elimination of those cancer cells by T cells. From the opposite point of view, if a person’s MHC-I molecule does not recognize and display a cancer antigen, that particular abnormality is more likely to show up in that person’s tumor. This played out clinically, too — the researchers found that the fewer the cancer antigens a person’s MHC-I can recognize, the earlier in life they’re likely to get cancer.

Carter said that it’s possible this information could someday be used to predict the type of cancer a person might get, how it might behave and how it might best be treated, all before the tumor even gets started.

But MHC-I doesn’t tell the whole story about the ability of a person’s immune system to respond to tumors. Humans also have a related molecule called MHC-II. MHC-I is displayed on the surface of every cell, and thus any cell with the potential to become cancerous. MHC-II, on the other hand, is only displayed by professional immune cells, such as macrophages. MHC-II is also a more complex molecule, and it can bind a larger range of antigens than MHC-I. Both molecules play an important role in keeping would-be tumors in check — while cancer cell precursors might be able to evade detection by one, they’re less likely to escape both.

New findings

Curious about the underappreciated member of the MHC family, Carter’s team focused on MHC-II in their latest study. Similar to their MHC-I study, they applied computational biology methods to data available from The Cancer Genome Atlas (TCGA), the National Institutes of Health’s database of genomic information from thousands of different human tumors. They scored 5,942 patient tumors based on the ability of their MHC-II molecules to present 1,018 cancer antigens for inspection by their CD4+ T cells.

The researchers found that an antigen that is well recognized by a person’s MHC-II is less likely to show up in his or her tumor than a mutation overlooked by MHC-II. This was even more true for MHC-II than MHC-I.

However, Carter and team were surprised to find that, unlike MHC-I, MHC-II’s ability to recognize antigens had no correlation with the age at which a person was diagnosed with cancer.

“Imagine there are 100 mutated antigens that can cause cancer,” Carter said. “If a person’s MHC-I can only present 20 of those antigens, they would have less coverage than someone who can present 80. When people can’t present a lot of mutations, they tend to get cancer at an earlier age. That’s true for MHC-I, but we couldn’t find that same correlation for MHC-II, at least not in this early analysis.”

Looking ahead

MHC-II is more complex than MHC-I, and the tools for studying MHC-II are not yet as sophisticated, Carter said. But as the field advances, she hopes to see researchers and clinicians take both MHC-I and MHC-II data into account when developing and personalizing cancer immunotherapies. She believes this information could help determine why some people respond to immunotherapy and others don’t. What’s more, she hopes doctors might someday be able to use MHC-I and -II readouts to predict a patient’s response before they are given immunotherapy, sparing non-responding patients from the potential side effects of ineffective therapies.

“Bringing MHC into the big picture of cancer through genomic analysis is a powerful new way to integrate the master regulator of immunity into a better understanding of cancer evolution and its dynamic interplay with the immune system,” said study co-author Maurizio Zanetti, MD, professor of medicine at UC San Diego School of Medicine and head of the Laboratory of Immunology at Moores Cancer Center. “This may represent a step forward in our ability to select the best form of immunotherapy for individual patients and likewise help better predict response to immunotherapy. I see this work as a major step to bridge cancer genomics and cancer immunity.”

Source:

https://health.ucsd.edu/news/releases/Pages/2018-09-20-cancer-immunotherapy-might-benefit-from-previously-overlooked-immune-players.aspx

Tagged with:

About author

Related Articles